Pam – Interview 21
Pam has breast cancer which spread to her bones and liver. She joined an open-label expanded access study of lapatinib and capecitabine, before lapatinib was licensed for general use. She left the study after lapatinib stopped working. (Wife of Tony, Interview 36)
Pam was diagnosed with breast cancer in 2002. She was successfully treated with surgery and tamoxifen, but in 2005 she discovered a bony lump and was told the cancer had spread to her bones. Further tests showed she also had a tumour in her liver. This was treated with chemotherapy, then further breast cancer was discovered, and Pam took taxol and herceptin, followed by herceptin on its own. Things remained stable for about a year, and then it was found that the tumour in her liver had doubled in size. At this point, she was offered tablets combining two drugs, lapatinib and capecitabine. These drugs had already been researched in randomised clinical trials, but lapatinib had not yet been licensed for use in the UK (until licensing was approved in July 2008). Women who were eligible could only be given the drug as part of a supervised study monitoring effectiveness and side effects – an open label expanded access; study. (Open label; means both the patient and doctor know what drug is being taken).
Pam felt the study was a lifeline and she was grateful for the chance to take part. She thinks she probably would have agreed to take part even if it had been a randomised trial and there was a chance she wouldn’t get the trial drug. At the time of the interview her liver tumour had shrunk back to a smaller size than it had been when she was taking taxol and herceptin, so she was very pleased with the results, and continues to try to live life to the full. There were some unpleasant side effects – some of her toenails have fallen out, and she has had considerable swelling and soreness in her hands and feet. At first she experienced bad diarrhoea but that was successfully controlled with additional tablets. She has regular scans and careful monitoring of her symptoms. At one point early on when she was experiencing a lot of side effects, she was taken off the drug for a while to allow her body to recover. That was the only time she thought about withdrawing from the study, but she describes herself as a fighter and was determined to carry on as long as she could. Shortly after the interview, Pam was told the lapatinib was no longer working so she was taken off the study, but she is still glad it helped for seven months.
Pam feels she was well-informed about the purpose of the study and the possible side effects, and that the choice to take part was entirely left to her. Her main reason for taking part was because of the possible benefit to herself, but she has offered to speak to anyone else involved in the trial who would like someone to talk to for support. Most people cannot appreciate what it is like, but patients can provide each other with a lot of sympathy and understanding. Pam is motivated by showing other people you can live a good life with cancer, and wants to encourage others to keep going. Her Jewish faith provides continuing inspiration.
She advises other people to give positive consideration to taking part in a trial if their doctor offers it. She is concerned that not everyone has the chance to take part in the study and gain access to the drug. She suggests health professionals should explain everything clearly and simply; appreciate how stressed and uncertain their patients are feeling; answer questions as often and as fully as needed; and encourage patients to bring someone with them who can help clarify the information.